EUVIMEDEUVIMED entdecken
Open Access

Benefits and Harms of Standard Versus Reduced‐Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation

Kaleen N Hayes iD, Tingting Zhang, Dae Hyun Kim, Lori A Daiello, Yoojin Lee, Douglas P Kiel, Sarah D Berry iD, Andrew R Zullo iD

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.029865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Kaleen N Hayes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services, Policy, and Practice Brown University School of Public Health Providence RI. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Dose reduction of direct oral anticoagulant (DOAC) medications is inconsistently applied to older adults with multiple morbidities, potentially due to perceived harms and unknown benefits of standard dosing. Methods and Results Using 2013 to 2017 US Medicare claims linked to Minimum Data Set records, we conducted a retrospective cohort study. We identified DOAC initiators (apixaban, dabigatran, rivaroxaban) aged ≥65 years with nonvalvular atrial fibrillation residing in a nursing home. We estimated inverse‐probability of treatment weights for DOAC dose using propensity scores. We examined safety (hospitalization for major bleeding) and effectiveness outcomes (all‐cause mortality, thrombosis [myocardial infarction, stroke, systemic embolism, venous thromboembolism]). We estimated hazard ratios (HRs) and 95% CIs using cause‐specific hazard‐regression models. Of 21 878 DOAC initiators, 48% received reduced dosing. The mean age of residents was 82.0 years, 66% were female, and 31% had moderate/severe cognitive impairment. After estimating inverse‐probability of treatment weights, standard dosing was associated with a higher rate of bleeding (HR, 1.18 [95% CI, 1.03–1.37]; 9.4 versus 8.0 events per 100 person‐years). Standard‐dose therapy was associated with the highest rates of bleeding among those aged >80 years (9.1 versus 6.7 events per 100 person‐years) and with a body mass index

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeAgedFemaleHumansUnited StatesAged, 80 and overMaleRetrospective StudiesFactor Xa InhibitorsMedicareAnticoagulantsRivaroxabanDabigatranHemorrhageMorbidityAdministration, Oral

Stichwörter der Autor:innen

Editorialsagingatrial fibrillationcomparative effectiveness researchfactor Xa inhibitorsfrail elderly

Substanzen

Factor Xa InhibitorsAnticoagulantsRivaroxabanDabigatran

Autor:innen und Institutionen

  • Department of Health Services, Policy, and Practice Brown University School of Public Health Providence RI.
  • Graduate Department of Pharmaceutical Sciences University of Toronto Leslie Dan Faculty of Pharmacy Toronto ON Canada.
  • Hinda and Arthur Marcus Institute for Aging Research Hebrew SeniorLife and Harvard Medical School Boston MA.
  • Division of Gerontology, Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA.
  • Department of Neurology Warren Alpert Medical School of Brown University and Alzheimer's Disease and Memory Disorders Center At Rhode Island Hospital Providence RI.

ORCID-Profile: Kaleen N Hayes, Sarah D Berry, Andrew R Zullo

Förderung

  • NIA NIH HHS

Zitieren

APA

Hayes, K. N., Zhang, T., Kim, D. H., Daiello, L. A., Lee, Y., Kiel, D. P., Berry, S. D., & Zullo, A. R. (2023). Benefits and Harms of Standard Versus Reduced‐Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.029865

Vancouver

Hayes KN, Zhang T, Kim DH, Daiello LA, Lee Y, Kiel DP, et al. Benefits and Harms of Standard Versus Reduced‐Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.029865

BibTeX
@article{Hayes2023,
  author = {Hayes, Kaleen N and Zhang, Tingting and Kim, Dae Hyun and Daiello, Lori A and Lee, Yoojin and Kiel, Douglas P and Berry, Sarah D and Zullo, Andrew R},
  title = {Benefits and Harms of Standard Versus Reduced‐Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.029865}
}
Kostenlos starten →